True adrenal cyst mimicking renal cancer in a young woman: a case report

The adrenal cyst is a rare disease that represents approximately 5% of discovered adrenal lesions, which are usually discovered incidentally. True adrenal cysts originate to cells from mesothelium. The potential of cyst adrenal to become malignant has been reported to be 7% and a radical excision of a potentially malignant mass are indicate. We report a case of a 48 year old woman that presented with pain in left hypochondrium and epigastrium, nausea, vomiting, weight loss and microscopic hematuria. After the diagnosis suspicion surgery was performed with a monoblock resection of left kidney and left adrenal gland because of kidney cancer diagnosis as considered. The microscopically analysis of surgical specimen, diagnosed a true epithelial cyst of adrenal gland

Cistos esplênicos não-parasitários

Este artigo apresenta uma revisão geral do tema, com ênfase em conceitos atuais e no manejo das situações clínicas em questão, em especial a conceitos referentes ao tratamento. Também é feita uma revisão extensa quanto à etiologia e seguimento dos pacientes com cisto esplênico não parasitário. São citadas informações derivadas dos principais estudos clínicos publicados na literatura médica atual

Tumor de células gigantes de fémur distal com metástases pulmonares

Resumo: O tumor de células gigantes é uma lesão óssea primária benigna que acomete a epífise de ossos longos, com maior incidência na terceira e quarta décadas de vida, mas que pode apresentar comportamento de um tumor maligno, com metástases à distância. Até dez por cento dos doentes podem apresentar metástases à distância, principalmente para o pulmão, geralmente acompanhadas de recidiva no local primário. O tratamento do tumor primário é a ampla ressecção cirúrgica. Os autores relatam o caso de um doente com 35 anos com metástases pulmonares 21 meses após ter realizado curetagem de tumor de células gigantes em fémur distal. Abstract: Gian cell is normally a benign primary skeletal lesion located in the epiphysis of the long bones. It is more frequente in the third and fourth decades of life but can exhibit the behaviour of a malignant tumour with distal metatasis. Up to 10% of patients present distal metatasis, usually in the lung, and it is concomitant to recurrence in the primary site. The treatment of primary tumour is extensive surgical resection. We report a case of a 35-year-old patient with lung metatases 21 months after curettage of giant cell tumour in distal femur. Palavras-chave: Tumor de células gigantes, neoplasias ósseas, metástases pulmonares, Key-words: Giant cell tumor, bone neoplasm, pulmonary metastase

Tumor de células gigantes de fémur distal com metástases pulmonares Giant cell tumour of distal femur with pulmonary metastases

O tumor de células gigantes é uma lesão óssea primária benigna que acomete a epífise de ossos longos, com maior incidência na terceira e quarta décadas de vida, mas que pode apresentar comportamento de um tumor maligno, com metástases à distância. Até dez por cento dos doentes podem apresentar metástases à distância, principalmente para o pulmão, geralmente acompanhadas de recidiva no local primário. O tratamento do tumor primário é a ampla ressecção cirúrgica. Os autores relatam o caso de um doente com 35 anos com metástases pulmonares 21 meses após ter realizado curetagem de tumor de células gigantes em fémur distal.Gian cell is normally a benign primary skeletal lesion located in the epiphysis of the long bones. It is more frequente in the third and fourth decades of life but can exhibit the behaviour of a malignant tumour with distal metatasis. Up to 10% of patients present distal metatasis, usually in the lung, and it is concomitant to recurrence in the primary site. The treatment of primary tumour is extensive surgical resection. We report a case of a 35-year-old patient with lung metatases 21 months after curettage of giant cell tumour in distal femur

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

Background: Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. To attempt to identify prognostic and predictive biomarkers, retrospective analyses were used to assess tumour (HER2, VEGFR2) and serum (VEGF-C and -D, and soluble (s) VEGFR1 and 3) biomarkers in phase 3 REGARD patients with metastatic gastric/gastroesophageal junction carcinoma. Methods: A total of 152 out of 355 (43%) patients randomised to ramucirumab or placebo had ⩾1 evaluable biomarker result using VEGFR2 immunohistochemistry or HER2, immunohistochemistry or FISH, of blinded baseline tumour tissue samples. Serum samples (32 patients, 9%) were assayed for VEGF-C and -D, and sVEGFR1 and 3. Results: None of the biomarkers tested were associated with ramucirumab efficacy at a level of statistical significance. High VEGFR2 endothelial expression was associated with a non-significant prognostic trend toward shorter progression-free survival (high vs low HR=1.65, 95% CI=0.84,3.23). Treatment with ramucirumab was associated with a trend toward improved survival in both high (HR=0.69, 95% CI=0.38, 1.22) and low (HR=0.73, 95% CI=0.42, 1.26) VEGFR2 subgroups. The benefit associated with ramucirumab did not appear to differ by tumoural HER2 expression. Conclusions: REGARD exploratory analyses did not identify a strong potentially predictive biomarker of ramucirumab efficacy; however, statistical power was limited

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. To attempt to identify prognostic and predictive biomarkers, retrospective analyses were used to assess tumour (HER2, VEGFR2) and serum (VEGF-C and -D, and soluble (s) VEGFR1 and 3) biomarkers in phase 3 REGARD patients with metastatic gastric/gastroesophageal junction carcinoma. A total of 152 out of 355 (43%) patients randomised to ramucirumab or placebo had ⩾1 evaluable biomarker result using VEGFR2 immunohistochemistry or HER2, immunohistochemistry or FISH, of blinded baseline tumour tissue samples. Serum samples (32 patients, 9%) were assayed for VEGF-C and -D, and sVEGFR1 and 3. None of the biomarkers tested were associated with ramucirumab efficacy at a level of statistical significance. High VEGFR2 endothelial expression was associated with a non-significant prognostic trend toward shorter progression-free survival (high vs low HR=1.65, 95% CI=0.84,3.23). Treatment with ramucirumab was associated with a trend toward improved survival in both high (HR=0.69, 95% CI=0.38, 1.22) and low (HR=0.73, 95% CI=0.42, 1.26) VEGFR2 subgroups. The benefit associated with ramucirumab did not appear to differ by tumoural HER2 expression. REGARD exploratory analyses did not identify a strong potentially predictive biomarker of ramucirumab efficacy; however, statistical power was limited